Cardiac hypertrophy HDAC2 has been shown to play a role in the regulatory pathway of cardiac hypertrophy. Deficiencies in HDAC2 were shown to mitigate cardiac hypertrophy in hearts exposed to hypertrophic stimuli. However, in HDAC2 transgenic mice with inactivated glycogen synthase kinase 3beta (Gsk3beta), hypertrophy was observed at a higher frequency. In mice with activated Gsk3beta enzymes and HDAC2 deficiencies, sensitivity to hypertrophic stimulus was observed at a higher rate. The results suggest regulatory roles of HDAC2 and GSk3beta.Mechanisms by which HDAC2 responds to hypertrophic stress have been proposed, though no general consensus has been met. One suggested mechanism puts forth
casein kinase dependent
phosphorylation of HDAC2, while a more recent mechanism suggests acetylation regulated by p300/CBP-associated factor and
HDAC5. Furthermore, a recent study found that inhibition of HDAC2 via c-Abl by
tyrosine phosphorylation prevented cognitive and behavioral impairments in mice with Alzheimer's disease. The results of the study support the role of c-Abl and HDAC2 in the signaling pathway of gene expression in patients with Alzheimer's disease. Currently, efforts to synthesize an HDAC2 inhibitor for the treatment of Alzheimer's disease are based on a
pharmacophore with four features: one hydrogen bond acceptor, one hydrogen bond donor, and two aromatic rings. Current research is focused on creating inhibitors that decrease the upregulation of HDAC2.
Anti-influenza virus factor HDAC2 plays a role in regulating the Signal Transducer and Activator of Transcription I (STAT1) and interferon-stimulated gene such as viperin. This shows that HDAC2 might be a component of cellular innate antiviral response. To circumvent the anti-viral potential, influenza A virus dysregulates HDAC2 by inducing its degradation by proteasomal degradation. == Interactions ==